Octapharma’s balanced portfolio built on a very special juice
Octapharma’s balanced portfolio built on a very special juice
Khair, Kate
2013-05-01 00:00:00
AbstractOctapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngThe Journal of Haemophilia Practicede Gruyterhttp://www.deepdyve.com/lp/de-gruyter/octapharma-s-balanced-portfolio-built-on-a-very-special-juice-GU1cuiEGHW
Octapharma’s balanced portfolio built on a very special juice
AbstractOctapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.